SCA
GTHX

Secor Capital Advisors’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Secor Capital Advisors’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-37,205
Closed -$618K – 286
2019
Q1 		$618K Buy
37,205
+4,614
+14% +$87.5K 0.13% 239
2018
Q4 		$624K Buy
+32,591
New +$1.22M 0.08% 285

Other funds holding GTHX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Secor Capital Advisors's GTHX Position: Q2 2019 in Review

Secor Capital Advisors sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2019, closing a stake of 37,205 shares — an estimated $618K sold.

Secor Capital Advisors first reported a position in GTHX in Q4 2018 and held it in 2 quarters. The position peaked at $624K in Q4 2018. 94 funds tracked by Wall St. Rank hold GTHX as of Q2 2019.

  • Secor Capital Advisors reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Secor Capital Advisors sold 37,205 G1 Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $618K.
  • Secor Capital Advisors first reported a position in G1 Therapeutics, Inc. Common Stock in Q4 2018 and held it in 2 quarters.
  • Secor Capital Advisors's G1 Therapeutics, Inc. Common Stock position peaked at $624K in Q4 2018.
  • 94 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Secor Capital Advisors's 13F filing for Q2 2019.